S. Chawla

发表

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

G. Demetri, M. von Mehren, J. Hamm, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

R. Advani, E. Jacobsen, L. F. Allen, 2015, British journal of haematology.

Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.

K. Ganjoo, S. Schuetze, S. Wieland, 2017 .

Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial

J. Blay, G. Demetri, A. Tolcher, 2007 .

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

K. Savage, P. Zinzani, S. Horwitz, 2013 .

Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study

David M. Thomas, J. Blay, M. Roudier, 2008 .

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

S. Sleijfer, S. Litière, A. Cesne, 2016, Gynecologic oncology.

Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.

T. D. de Reijke, J. Witjes, T. Reijke, 2012, The Journal of urology.

PHASE II MARKER LESION STUDY WITH INTRAVESICAL INSTILLATION OF EOQUIN TM IN SUPERFICIAL BLADDER CANCER, TOXICITY AND MARKER RESPONSE - THE FINAL RESULTS

J. Witjes, T. Reijke, H. Vergunst, 2006 .

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

I. Láng, L. Schwartzberg, S. Chawla, 2020, Cancer medicine.

Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial

L. Schwartzberg, I. Mehmi, S. Chawla, 2020, The oncologist.

Justification for a Fixed Dose of Eflapegrastim, a Long‐Acting G‐CSF, in Patients Receiving Docetaxel‐Cyclophosphamide Chemotherapy

J. Barrett, S. Lakshmikanthan, S. Chawla, 2020, Journal of clinical pharmacology.

belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153

P. Zinzani, S. Horwitz, O. O’Connor, 2013 .

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

J. Blay, G. Demetri, F. Grosso, 2013, British Journal of Cancer.

Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide.

J. Blay, G. Demetri, M. von Mehren, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

K. Savage, S. Horwitz, L. F. Allen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

J. Blay, G. Demetri, J. Radford, 2010 .

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma

P. Reimer, S. Chawla, 2013, Journal of Hematology & Oncology.

Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)

Robin L. Jones, M. Burgess, A. Italiano, 2019, Annals of Oncology.

Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021

Robin L. Jones, A. Italiano, R. Riedel, 2016 .

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

S. Ferrari, P. Picci, K. Sankhala, 2017, European journal of cancer.

A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).

Jonathan J. Lewis, R. Maki, C. Ryan, 2010 .

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

A. Drilon, J. Krauss, R. Doebele, 2020 .

Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)

A. Cesne, S. Schuetze, P. Casali, 2007 .

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

J. Beijnen, J. Double, P. Loadman, 2006, The Journal of urology.

Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

J. Crowley, D. Reinke, R. Benjamin, 2010 .

A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.

J. Crowley, D. Reinke, R. Maki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072).

J. Blay, A. Cesne, A. D. Dei Tos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC).

V. Picozzi, A. Ocean, S. Chawla, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas

G. Demetri, C. Bedrosian, K. Sankhala, 2005 .

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

S. Sleijfer, S. Litière, J. Verweij, 2015, European journal of cancer.

Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study.

P. Rutkowski, I. Jacobs, R. Grimer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

J. Blay, G. Demetri, A. Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

J. Blay, G. Demetri, A. Tolcher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.